FDA Issues Draft Guidance to Reduce Animal Testing

FDA issues draft guidance to reduce animal testing

FDA has published a draft guidance to incentivize drug developers to use and validate new approach methodologies, or NAMS, as part of a broader effort to move away from animal testing.  This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renewing ($60), and Sponsored account members only. Visit the site and log in/register to read.The pos…

MHRA & FDA non animal drug development alignment

It’s been a landmark two weeks for the industry. The US FDA and the UK MHRA have taken monumental steps to reduce regulatory uncertainty, one of the biggest barriers to the adoption of New Approach Methodologies (NAMs). In this news post, we discuss how recent MHRA and FDA non-animal drug development guidance aligns. We show how the human-relevant, mechanistic data from CN Bio’s PhysioMimix® Core microphysiological system fits their needs in mod…